Weight Regain After Stopping Semaglutide or Tirzepatide: What the Trials Show

People often treat a GLP-1 or dual GIP/GLP-1 agonist like a short course. The trial data do not. When semaglutide or tirzepatide stops, most of the lost weight comes back, and a large share of the cardiometabolic improvement comes back with it. That is not a failure of the peptide. It is what you would expect if obesity is a chronic, defended physiology and the drug is the thing holding that defense down.

This article walks through the withdrawal trials and the biology behind the rebound. Educational only — not medical advice, and not a recommendation to start or stop any medication.

The pattern is consistent

Three randomized designs asked the same question in slightly different ways: what happens if you take the peptide away after people have already lost a lot of weight?

STEP 1 extension (semaglutide). After the 68-week STEP 1 obesity trial, a subset of participants stopped both once-weekly semaglutide 2.4 mg and the lifestyle intervention and were followed for another year. One year off treatment they had regained two-thirds of the weight they had lost, and cardiometabolic variables moved in the same direction (Wilding et al., 2022). Regain was still underway at week 120. The peptide had not reset body weight to a new permanent floor.

STEP 4 (semaglutide, randomized withdrawal). This design is cleaner because the stop was randomized. Everyone received semaglutide during a 20-week run-in, then continued the drug or switched to placebo for 48 weeks. People who stayed on semaglutide lost another 7.9% of body weight. People switched to placebo gained 6.9% back. The between-group gap was 14.8 percentage points (Rubino et al., JAMA 2021).

SURMOUNT-4 (tirzepatide). After 36 weeks of open-label tirzepatide, mean weight change was about −20.9%. Participants were then randomized to continue or switch to placebo for 52 weeks. Continuation produced another 5.5% loss. Placebo produced a 14.0% regain. From original baseline to week 88, that left about −25.3% with ongoing tirzepatide versus −9.9% after withdrawal. Nearly 90% of people who stayed on the drug kept at least 80% of their lead-in loss; only about 17% of the placebo group did (Aronne et al., 2024).

A 2026 post-hoc look at the SURMOUNT-4 withdrawal arm is more specific: 82% of participants who stopped tirzepatide regained more than a quarter of the weight they had lost within a year, and the more they regained, the more waist circumference, blood pressure, lipids, and A1c reversed (Horn et al., 2026).

This is not unique to one brand

A January 2026 BMJ systematic review pooled 37 studies and more than 9,000 participants across weight-management medications. After the drugs stopped, people regained about 0.4 kg per month on average. The authors projected a return toward baseline weight in roughly 1.7 years, with cardiometabolic markers following on a similar clock (West et al., 2026). Regain after incretin-based drugs was faster than after behavioral programs alone, which is another way of saying the pharmacology is doing real work while it is on board.

If you want the on-treatment comparison between the two most-used agents, that lives in tirzepatide vs semaglutide. The withdrawal data answer a different question: not which peptide is stronger, but whether the effect holds once the peptide is gone.

Why the weight comes back

GLP-1 receptor agonists, and dual GIP/GLP-1 agonists such as tirzepatide, reduce energy intake. They slow gastric emptying, amplify satiety signaling, and quiet the food noise people describe when they start treatment. None of those effects is a permanent rewrite of the hypothalamus.

Weight loss itself also flips a set of counter-regulatory hormones. In the classic Sumithran study, people who lost weight by diet still had higher ghrelin, lower leptin, and more hunger a full year later (Sumithran et al., 2011). The body defends its prior weight. A circulating peptide can override that defense. When the peptide leaves, the defense is still there.

That is the same logic as stopping a blood-pressure drug and watching the pressure rise. It does not mean the drug never worked.

What the data do not say

They do not say everyone returns to their exact starting weight on a fixed timetable. In SURMOUNT-4, people who stopped still sat about 10% below their original baseline at week 88. They do not say lifestyle is irrelevant. They do not tell you a maintenance dose, a taper schedule, or a stacking protocol. Those questions belong in a clinic.

They also do not mean the only future is indefinite full-dose monotherapy. Combination incretin and amylin programs such as CagriSema exist partly because a second satiety pathway may change how much weight people can keep off. Lean-mass preservation during loss is a separate issue, covered in GLP-1s and muscle. None of that is a do-it-yourself plan.

How to use this if you are comparing options

If you are looking at branded, compounded, or telehealth routes, start with the provider directory and the price index rather than forum stories about cycling off. If you are still mapping the category, Peptides 101 is the beginner frame. Clinician voices live on the experts page.

The useful takeaway from the withdrawal trials is simple and pro-peptide: these molecules do what they are supposed to do while they are present. Obesity physiology does what it is supposed to do when they are not. Planning for maintenance is part of using them honestly, not a reason to dismiss them.